Korean J Med.  2004 Jul;67(1):94-99.

A case of posttransplantation lymphoproliferative disease developed in renal transplant recipient and treated with rituximab

• Park US
• Choi CB
• Kim IS
• Choi IY
• Kang JM
• Park CK
• Ahn MJ

Abstract

Posttransplant lymphoproliferative disorder (PTLD) are among the most serious and potentially fatal complications of chronic immunosuppression in organ transplant recipient and also the most common malignancies, accounting for 21 percent of all malignancies in organ transplants versus 5 percent of malignancies in the general population. PTLD is associated with immunosuppression and Epstein Barr virus (EBV). Treatment modality of PTLD includes antiviral agent, interferon, intensive chemotherapy and monoclonal antibody. Choice of treatment modality depends on clinical presentation of PTLD. We report here a case of PTLD involving liver and renal allograft treated with rituximab.

Keyword

Posttransplant lymphoproliferative disorder; Rituximab; Renal transplantation

MeSH Terms

Allografts
Drug Therapy
Herpesvirus 4, Human
Immunosuppression
Interferons
Kidney Transplantation
Liver
Lymphoproliferative Disorders
Transplantation*
Transplants
Rituximab
Interferons